Conclusion: -
Pruritus is a common symptom in patients with PV resulting in
significant morbidity. Amongst the many medications available for
symptom control, ruxolitinib seems to be the most effective in managing
PV-related pruritus. So, this case report sheds light on using
ruxolitinib as the first-line treatment of refractory pruritus in PV
patients.